Sarepta Therapeutics, Inc. - Common Stock — 현금 흐름 (NASDAQ:SRPT)

Financials

영업활동으로 인한 현금 107.47 M-443.17 M-325.35 M-500.99 M-205.79 M-205.48 M 175.28 M 투자 활동으로 인한 현금 -121.72 M495.41 M-1.05 B-165.8 M755.56 M69.64 M 226.43 M 재무활동으로 인한 현금 682.32 M561.57 M232.51 M125 M124.81 M-168.34 M -180.57 M 잉여 현금 흐름 107.47 M-443.17 M-325.35 M-500.99 M-205.79 M-315.33 M 108.23 M

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

SRPT

Financials

Sarepta Therapeutics, Inc. - Common Stock

뉴스

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

Stock Market Soars On Tumbling Oil Prices, Strong Earnings: Weekly Review

Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained

Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?

Sarepta Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:SRPT) 2026-05-06

Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates